Last reviewed · How we verify

NCT06763484: MENOXTINA

Paroxetine Versus Placebo for Vasomotor Symptom Management in Surgical Menopause

Completed Phase 2 Last updated 17 September 2025
What this trial tests

Phase 2 trial testing Paroxetine in Menopause Syndrome in 90 participants. Completed in 1 September 2025.

Timeline
30 January 2025
Primary endpoint
31 July 2025
1 September 2025

Quick facts

Lead sponsorUniversidad Nacional Autonoma de Honduras
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment90
Start date30 January 2025
Primary completion31 July 2025
Estimated completion1 September 2025
Sites1 location across Honduras

Drugs / interventions tested

Conditions studied

Sponsor

Universidad Nacional Autonoma de Honduras — full company profile →

Who can join

Adults 18 to 80, female only, with Menopause Syndrome or Menopause Surgical. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

evaluate the efficacy of paroxetine in the management of vasomotor symptoms in patients with surgical menopause, in order to seek an alternative therapy to hormone therapy, which is associated with proinflammatory and procoagulant effects that increase the risk of thrombosis and is therefore contraindicated in people with diabetes mellitus, chronic arterial hypertension and patients with a history of thromboembolism

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Paroxetine

Trials testing the same drug.

Other Universidad Nacional Autonoma de Honduras trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06763484.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing